PerkinElmer launches new MicroBeta2 microplate counter
platform
25 January 2009
PerkinElmer, Inc., has launched its MicroBeta2 microplate
counter platform, for enabling improved radiometric and luminescent
detection in drug discovery and basic life science research.
The MicroBeta2 and MicroBeta2 LumiJET systems are the latest versions
of PerkinElmer’s MicroBeta line and add new and improved capabilities
for researchers engaged in all major radiometric and luminescence
applications. The MicroBeta2 platform is designed for robust
performance with both radiometric and glow luminescent assays.
Sensitive detection is achieved through coincidence counting, for
high efficiency and extremely low background for a wide variety of
radionuclides. By combining liquid scintillation counter reliability
with plate reader simplicity, the system allows significant savings in
time and consumables, while reducing waste.
“The newest version of the MicroBeta2 system further
provides researchers with an entry path to the benefits of
luminescent-based technologies in addressing many potential drug
targets,” said Richard M. Eglen, PhD, president, Bio-discovery,
PerkinElmer. “Leveraging PerkinElmer’s long leadership in radiometric
detection solutions, the MicroBeta2 platform further represents a
flexible system for either radiometric detection, or luminescent drug
discovery assays.”
Bookmark this page